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Abstract 
The renin angiotensin system (RAS) consists of the systemic hormone system, critically involved in regulation and 
homeostasis of normal physiological functions [i.e. blood pressure (BP), blood volume regulation], and an independ-
ent brain RAS, which is involved in the regulation of many functions such as memory, central control of BP and 
metabolic functions. In general terms, the RAS consists of two opposing axes; the ‘classical axis’ mediated primarily 
by Angiotensin II (Ang II), and the ‘alternative axis’ mediated mainly by Angiotensin-(1–7) (Ang-(1–7)). An imbalance 
of these two opposing axes is thought to exist between genders and is thought to contribute to the pathology of 
cardiovascular conditions such as hypertension, a stroke co-morbidity. Ischaemic stroke pathophysiology has been 
shown to be influenced by components of the RAS with specific RAS receptor antagonists and agonists improving 
outcome in experimental models of stroke. Manipulation of the two opposing axes following acute ischaemic stroke 
may provide an opportunity for protection of the neurovascular unit, particularly in the presence of pre-existing 
co-morbidities where the balance may be shifted. In the present review we will give an overview of the experimental 
stroke studies that have investigated pharmacological interventions of the RAS.
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Background
In the UK, stroke is the fourth leading cause of death and 
one of the largest contributors towards long-term dis-
ability, affecting approximately 152,000 people every year 
(https://www.stroke.org.uk; State of the Nation 2015) [1]. 
In the past 40  years the number of stroke fatalities has 
been decreasing, however, it is estimated that over two-
thirds of stroke survivors require daily medical care and 
over half are left disabled [2], resulting in an annual cost 
of nearly £4 billion and accounting for approximately 
4–6 % of total NHS expenditure [3].
Recombinant tissue plasminogen activator (rt-PA; 
Alteplase), is the only thrombolytic treatment cur-
rently available for acute ischaemic stroke (AIS). It acts 
by breaking down the clot or thrombus obstructing the 
cerebral vessel, thus, re-establishing blood flow. However, 
it has a narrow therapeutic time window of 4.5  h from 
stroke onset, resulting in only 2–5 % of ischaemic strokes 
being treated globally, and can have detrimental side 
effects, including haemorrhage [4]. Recent results from 
a number of randomised clinical trials of mechani-
cal thrombectomy have demonstrated efficacy for this 
intervention up to 6 h after stroke onset [5]. The positive 
results from these trials have reinvigorated the stroke 
community and open up new possibilities for adjunctive 
protective strategies.
Failure to translate effective therapeutic strategies from 
the ‘bench to bedside’ may partly be attributed to the use 
of animal models that do not incorporate non-modifiable 
risk factors such as gender and many of the stroke co-
morbidities observed in the clinical stroke population, 
such as hypertension, diabetes, obesity, etc. For instance, 
hypertension is the single most important modifiable risk 
factor for stroke, acting as a contributing factor in over 
75  % of first time stroke patients [6] with hypertension 
during acute stroke is associated with poorer clinical out-
come [7].
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The renin angiotensin system (RAS), a peptide hor-
mone system intrinsically involved in blood pressure reg-
ulation and blood volume homeostasis in the circulation, 
has been shown to be present as a local paracrine system 
in the brain [8]. The RAS is reported to be involved in 
the pathology of AIS and its risk factors [8, 9], therefore, 
emerging as a potential therapeutic target. This review 
discusses the therapeutic potential of the RAS following 
AIS, emphasising the importance of cerebral RAS recep-
tor targeting and its relevance in the presence of known 
stroke risk factors.
Brain RAS: classical and alternative axis
In the circulation, a drop in blood pressure (systemic 
hypotension) and/or blood volume results in juxtaglo-
merular cells within the kidneys to release renin (pro-
tease) whereas increased blood pressure (hypertension) 
inhibits renin release under normal circumstances. 
Circulating angiotensinogen is hydrolysed by renin to 
produce Angiotensin I (Ang I), which is then further con-
verted by angiotensin converting enzyme (ACE) to gen-
erate biological active octapeptide, Ang II (Fig. 1). Ang II, 
a potent vasoconstrictor, acts by stimulating Ang II type 1 
and type 2 receptors (AT1R and AT2R) [10]. Ang II exhib-
its a higher affinity to the widely expressed AT1R whereby 
it exerts its main physiological effects by constricting 
blood vessels, increasing BP, and stimulating aldoster-
one release from adrenal glands, promoting water and 
salt reabsorption in the kidneys, thus, raising blood vol-
ume levels [10]. In the last decade, an ‘alternative axis’ 
has been identified involving the monocarboxypeptidase, 
ACE2, the biologically active peptide Ang-(1–7) and its 
G-protein coupled receptor, Mas (MasR). Ang-(1–7) is 
formed by the direct actions of ACE2 on Ang II or via 
ACE2 induced cleavage of Ang I, generating the nine 
amino acid peptide Ang-(1–9), which is further con-
verted to Ang (1–7) by ACE or peptidases such as nepri-
lysin (NEP) [8].
All the components of the ‘classical axis’ (angiotensino-
gen, renin, ACE, Ang II) have been identified within 
the brain parenchyma (see reviews [8, 11]). In addition, 
there is evidence that the ‘alternative axis’ is locally pro-
duced within the brain as ACE2 has been localised in 
neurons [12], astrocytes [13] and within the cerebrovas-
culature [14]. Similarly, the receptor subtypes responsi-
ble for mediating the functional effects of RAS peptides 
are expressed in neuronal and glial cells throughout the 
brain. For example, AT1 and AT2 receptors have been 
shown to be present in dopaminergic neurons, astrocytes 
and microglia from both human and primate brain tissue 
[15] and MasR shown to be expressed in neurons, astro-
cytes, microglia and cerebral endothelial cells in rodents 
[16, 17].
Involvement in ischaemic stroke
Over-activation of the ACE/Ang II/AT1R axis is thought 
to contribute to the pathogenesis of AIS through its vaso-
constrictor effects on cerebral vessels as well as its pro-
inflammatory, pro-fibrotic and increased oxidative stress 
effects in the parenchyma [8]. For instance, in the brain, 
AT1R knockout (KO) mice subjected to permanent mid-
dle cerebral artery occlusion (pMCAO) exhibit a larger 
metabolic penumbra volume (cerebral protein synthe-
sis and ATP mismatch) and higher CBF within the core 
and penumbra when compared to wild type (WT) mice 
whereas mice over-expressing human renin and angio-
tensinogen genes have larger infarcts [18, 19]. Further-
more, Ang II has been shown to enhance the contractile 
response in isolated middle cerebral arteries (MCA) fol-
lowing MCAO via the AT1R [20], therefore, worsening 
cerebral perfusion following ischaemia.
Interestingly, emerging evidence identifies the ‘alterna-
tive axis’ as an endogenous protective system, which acts 
to counteract the effects of the ‘classical axis’ by mediat-
ing vasodilation and anti-inflammatory, anti-oxidant and 
anti-apoptotic effects via MasR and AT2R activation [21, 
22]. Following focal cerebral ischaemia in the rat, AT2Rs 
have been shown to be upregulated in the peri-infarct 
region of the cortex, and also within the selectively vul-
nerable regions of the cortex and hippocampus following 
global cerebral ischaemia [23, 24]. AT2R KO mice exhibit 
less ischaemic damage compared to WT control animals 
following MCAO [25] suggesting a protective role for 
this receptor in the setting of cerebral ischaemia. In sup-
port of a role for this pathway following acute ischaemic 
stroke the ACE2/Ang-(1–7)/Mas axis has been shown 
to be upregulated. Brain expression (mRNA and protein 
levels) of both ACE2 and MasR are upregulated from as 
early as 6 h following permanent MCAO in the rat, peak-
ing at 24  h post MCAO. This was associated with an 
concomitant increase in both circulating serum and cer-
ebral Ang-(1–7) levels [16]. This increase occurs during 
the first critical hours after stroke when ischaemic dam-
age and loss of potentially salvageable penumbra is tak-
ing place, suggesting a potential role for this pathway in 
the pathogenesis. Increasing exogenous Ang-(1–7) levels 
in the brain by central infusion prior to stroke has been 
shown to decrease infarct volume in rats [26], providing 
evidence of a protective role for this pathway post-stroke.
The current evidence suggests that there is an imbal-
ance in the RAS following stroke with an enhanced 
activation of the ACE/Ang II/AT1R pathway and that tar-
geting the counter-regulatory ACE2/Ang-(1–7)/Mas axis 
may provide protection. This imbalance in the RAS may 
be exacerbated in the presence of known stroke risk fac-
tors such as gender and hypertension and therefore pro-
vide a potential therapeutic target in a subset of patients.
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RAS and stroke co‑morbidities
Men have a higher incidence of stroke, however, after 
the menopause the incidence of stroke in women rap-
idly increases and this is co-incident with the decrease 
in female sex hormones [27]. In addition, to sex differ-
ences in stroke incidence, it is also well established in 
experimental stroke studies that female animals have less 
ischaemic injury than their male counterparts and that 
this protection is lost after ovariectomy [28, 29]. Further-
more, cells exhibit sex specific differences in the specific 
mechanisms of cell death following cerebral ischaemia 
[30] therefore it is not unlikely that sex differences will 
exist in the RAS in the brain and elsewhere. It is widely 
accepted that the RAS is influenced by sex hormones 
with males and females exhibiting differential responses 
to stimulation and inhibition of the RAS [31]. Differences 
in vascular reactivity to Ang II and receptor expression 
have been shown to be influenced by sex hormones, with 
testosterone stimulating the ‘classical axis’ and oestro-
gen lowering the AT1R:AT2R ratio, thereby enhancing 
vasodilatation [32–34]. Interestingly, in experimental 
animal models, female rats exhibit enhanced activity of 
the ACE2/Ang-(1–7)/Mas axis compared to males [31], 
showing increased renal Ang-(1–7) levels [35]. These 
findings may translate to humans, where normotensive 
healthy adult females have been shown to have higher 
plasma levels of Ang-(1–7) than their male counterparts 
[36]. These combined findings suggest that oestrogen 
may confer some degree of protection against stroke in 
premenopausal women by promoting increased activa-
tion of the ACE2/Ang-(1–7)/Mas axis and therefore, 
the loss of oestrogen associated with menopause may 
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Fig. 1 Simplified overview of the renin angiotensin system (RAS). Angiotensinogen is cleaved by renin generating Angiotensin I (Ang I) which is 
then formed into Angiotensin II (Ang II) via the actions of angiotensin converting enzyme (ACE). Ang II preferentially binds to Angiotensin II type I 
receptor (AT1R) (‘classical axis’) inducing vasoconstriction, inflammation, oxidative stress, apoptosis and cell proliferation. Ang II can also activate the 
Angiotensin II type II (AT2R) and is metabolised by angiotensin converting enzyme 2 (ACE2) to generate Angiotensin-(1–7). Ang-(1–7) activates the 
Mas receptor (MasR). Ang-(1–7) can be formed by the actions of ACE or neprilysin (NEP) on Angiotensin-(1–9) or Angiotensin I. AT2R and ACE2/Ang-
(1–7)/MasR form the ‘alternative axis’ and its activation is thought to counteract the detrimental effects induced by AT1R by leading to vasodilation, 
angiogenesis and preventing inflammation, oxidative stress and apoptosis
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contribute to increased stroke risk through a loss of this 
enhanced protective pathway. In terms of brain expres-
sion, AT1R expression has been shown to be lowered in 
rats treated with oestrogen plus ovariectomy compared 
to ovariectomy alone. In contrast, oestrogen treatment 
in ovariectomised rats resulted in an increased expres-
sion of the AT2R compared to ovariectomised rats [37]. 
Similarly, mRNA expression of the AT1R and ACE are 
increased in the brains of hypertensive ovariectomised 
rats compared to intact females [38].
Hypertension is the single most important modifi-
able risk factor for the development of stroke, clinical 
outcome is poorer in patients with hypertension dur-
ing acute stroke and in experimental animal models of 
stroke, ischaemic damage is significantly increased in 
hypertensive animals [39, 40]. Dysregulation of the RAS 
has been implicated in the development of hypertension, 
where hyperactivity of Ang II and other RAS compo-
nents lead to enhanced oxidative stress and inflamma-
tion. Preclinical models of genetic hypertension have 
demonstrated increased AT1R expression in the vascu-
lature of spontaneously hypertensive rats (SHR) com-
pared to age-matched normotensive controls [41]. In 
addition to hyperactivity of the ‘classical axis’, dampen-
ing of the protective counter-regulatory axis is also evi-
dent, where hypertensive rat strains exhibit decreased 
ACE2 mRNA and protein expression compared to nor-
motensive controls [42]. Chronic treatment of diabetic 
SHR rats with either an AT1R blocker (olmesartan) or 
ACE inhibitor (enalapril) reverses the microcirculatory 
changes that occur in pial vessels (functional and struc-
tural rarefaction) of the brain resulting in an improved 
cerebral perfusion and reduced cerebral oxidative stress 
[43]. Candesartan treatment in salt loaded SHRSP rats 
was shown to increase endothelial cell progenitor (EPC) 
colony number and reduce oxidative stress levels in mon-
onuclear cells. This study suggests that ARB treatment 
may also act to improve endothelial cell function and 
angiogenesis in the presence of hypertension [44]. These 
results demonstrate the influence of the ACE/Ang II/
AT1R pathway on remodelling of the cerebral microvas-
culature and suggest that overactivation of this pathway 
may contribute to the pathology.
Therefore, manipulation of the RAS towards the pro-
tective ACE2/Ang-(1–7)/MasR pathway in the presence 
of co-morbidities may shift the balance to prevent the 
exacerbation of ischaemic damage following AIS.
Therapeutic targeting of the RAS following stroke
AT1R blockers
Angiotensin type 1 receptor blockers (ARBs or “sartans”) 
have been widely used as a successful and established 
therapy for the treatment of clinical hypertension [45]. 
As a result, this class of drug has been assessed for pos-
sible neuroprotective effects in a number of experimental 
stroke studies (Table  1) [46–56]. Central administration 
of irbesartan (ARB) prior to transient middle cerebral 
artery occlusion (tMCAO) has been shown to improve 
neurological outcome with no effect on blood pressure, 
however one limitation was the lack of any measure of 
infarct volume [43]. Follow up studies demonstrated 
that administration of ARB’s prior to MCAO could in 
fact reduce infarct volume and this was associated with a 
reduction in the number of activated microglia and mac-
rophages (ED-1 staining) as well as a reduction in mark-
ers of apoptosis (TUNEL, PARP P85 staining and caspase 
3) [47, 56].
The cerebral vasodilatory potential of ARB’s have 
been extensively investigated and studies have exam-
ined its effects on isolated cerebral vessels as well as 
the cerebral blood flow (CBF) response in  vivo. Can-
desartan in particular, has shown the potential to 
increase cerebral perfusion following MCAO in both 
normotensive as well as hypertensive rats (SHR). In 
normotensive rats, administration of Candesartan 
as an i.v bolus (2  h prior to MCAO) was reported to 
increase CBF in the ipsilateral hemisphere both at 
baseline and during MCAO [57]. In SHRs, chronic 
candesartan infusion for 28  days prior to MCAO 
reduced infarct volume and this was associated with 
an improved CBF compared to vehicle treated rats, 
particularly in the cortical areas at the periphery of the 
infarct. In addition, isolated vessels taken at the end 
of the chronic treatment protocol demonstrated an 
increased MCA diameter and reduced media thickness 
suggesting chronic changes to cerebral vessels result-
ing in reduced hypertension induced remodelling and 
enhanced collateral flow [55]. Similarly, Nishimura and 
colleagues demonstrated that chronic pre-treatment 
with Candesartan improved cerebrovascular autoregu-
lation and decreased infarct size, an outcome associ-
ated with reduced AT1R binding in the MCA with Ang 
II autoradiography [54].
Other reported effects of AT1R blockade include pro-
angiogenic/neurogenic effects. For example, Candesar-
tan pre-treatment (at a dose with no BP effect) reduced 
infarct volume and increased mRNA expression of brain 
derived neurotrophic factor (BDNF) and its associated 
receptor (tropomyosin receptor kinase B; TrkB) 48 h after 
tMCAO [46]. Similarly, in SHR rats candesartan treat-
ment following MCAO was shown to increase BDNF 
protein levels [58], suggesting, a potential involvement in 
neuronal cell regeneration. Despite indications of neuro-
protection with blockade of the AT1R, not all experimen-
tal studies attenuated infarct evolution independently of 
BP lowering effects (Table 1).
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AT2R agonism
It has been proposed that the neuroprotective mecha-
nisms induced by ARB’s may partly involve increased 
Ang II binding to the AT2 receptor [59]. Consequently, 
selective AT2R agonists have been developed and investi-
gated in models of experimental stroke (Table 2) [60–67]. 
In normotensive rats, central and systemic administra-
tion of compound 21 (C21), a selective non-peptide 
and orally active AT2R agonist, prior to and post ET-1 
induced MCAO, reduces infarct size and improves neu-
rological deficit. This protective effect was attributed to a 
decrease in inflammatory markers, inducible nitric oxide 
synthase (iNOS) and C–C motif chemokine receptor 
type 2 (CCR2) mRNA expression in the cerebral cortex 
following tMCAO, an effect blocked by the AT2R selec-
tive antagonist PD123319 [62].
In conscious SHR rats, the AT2R agonist, CGP42112, 
attenuates lesion progression and improves motor func-
tion following tMCAO. These effects were independ-
ent of BP alterations and possibly due to enhanced 
AT2R receptor level expression, increased microglial 
activation and reduced superoxide production within 
the peri-infarct region [63, 64]. These findings are sup-
ported by in vitro data in primary cortical neurons where 
CGP42112 administration was shown to attenuate cell 
death following oxygen glucose depravation (OGD) [66]. 
Similarly, C21, was shown to dose dependently reduce 
infarct volume in SHR when administered centrally for 
5 days prior to endothelin 1 (ET-1) induced MCAO. This 
was associated with an increase in microglia activation 
within the infarct core and peri-infarct, however, when 
administered 6  h post-stroke the protective effect was 
still observed but there was no enhancement of micro-
glial activation [65].
Apart from an anti-inflammatory role, C21 has also 
been shown to promote angiogenesis. In primary corti-
cal neurones, C21 treatment 24  h post OGD challenge, 
enhances vascular endothelial growth factor (VEGF) via 
mechanistic targeting of rapamycin (mTOR) pathway 
activation [68]. Similarly, in in  vivo models, 28  day C21 
treatment in mice subjected to either transient or perma-
nent MCAO resulted in increased angiogenesis via VEGF 
upregulation and effect which the authors hypothesise is 
through an AT2R mediated activation of the P13K-Akt-
mTOR pathway [61]. Additionally, in ex vivo studies, vas-
odilation and increased perfusion seems to be dependent 
on the animal model used. Using wire myography, C21 
treatment in isolated basilar arteries causes cerebral ves-
sel relaxation, promoting vasodilation [59], an outcome 
supported by in  vivo studies where mice subjected to 
pMCAO with C21 pre-treatment had an improved CBF 
in the ischaemic hemisphere at days 1 and 3 following 
pMCAO. This was associated with a decreased infarct 
size, and attenuated blood brain barrier (BBB) break-
down as measured by Evans blue extravasation [67]. On 
the contrary, in mice subjected to tMCAO, C21 did not 
induce any acute changes in CBF when administered fol-
lowing reperfusion [68].
In contrast to the protective effects of C21 discussed 
above, a recent study showed that C21 did not affect 
infarct volume in mice 4  days following tMCAO; how-
ever, it did improve neurological score and mortal-
ity rates. Interestingly, the neurological improvement 
observed was associated with an increase in anti-apop-
totic and regenerative molecules BDNF, TrkB and growth 
associated protein 43 (GAP-43) in peri-infarct regions 
when compared to vehicle [68].
MasR agonism
Evidence suggests that AT2R interacts with other RAS 
mediators and its effects may be partly mediated by an 
interaction with the Mas receptor, which is activated by 
Ang-(1–7) [69]. Recently, the interaction between ACE2/
Ang-(1–7)/MasR in AIS has been studied and shown 
to be protective in several animal models (Table  3) [17, 
26, 70–73]. Mecca and colleagues were one of the first 
groups to identify the potential neuroprotective effects 
of this peptide and its receptor. They demonstrated that 
central administration of Ang-(1–7) for 7  days prior to 
ET-1 induced MCAO, reduced infarct volume via MasR 
activation and decreased cortical iNOS mRNA expres-
sion [26]. Further evidence now proposes that Ang-(1–
7) might have direct anti-inflammatory properties and 
specifically target microglia. In primary microglial cell 
cultures under basal conditions, MasR activation modu-
lates inflammatory marker expression by attenuating 
pro-inflammatory genes [74]. Following tMCAO injury, 
Ang-(1–7) treatment not only reduces iNOS mRNA and 
protein levels in ipsilateral cerebral cortex but attenuates 
chemokine C-X-C motif ligand 12 (CXCL12) levels at 6 h 
post tMCAO and interleukin (IL)-1β, IL-6  and cluster 
differentiation 11b (CD11b) at 24 h [17]. These findings 
are further supported by pMCAO studies, where Ang-
(1–7) decreased nuclear factor kappa B (NFκB) phospho-
rylation and cyclooxygenase-2 (COX-2) protein levels in 
peri-infarct regions when compared to vehicle [71].
The vasodilatory properties of Ang-(1–7) in cerebral 
vessels are conflicting. In canine MCA and piglet pial 
arterioles, Ang-(1–7) induces vasodilation in intact ves-
sels only at very high concentrations [75, 76]. However, 
Durand and colleagues demonstrated that in normo-
tensive isolated rat MCA’s, Ang-(1–7) dose dependently 
induced a vasodilator response which was blocked by 
Mas and AT2 receptor antagonists [77]. Ang-(1–7) 
mediated vasodilatation may vary depending on ani-
mal species. Nevertheless, in rodents, it is possible that 
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Ang-(1–7) might induce vasodilation in cerebral vessels 
due to increases in NO and/or bradykinin (BK) release. 
Central administration of Ang-(1–7) in a rat transient 
MCAO model has been shown to enhance nitric oxide 
(NO) release between 3 and 72 h after transient MCAO 
when compared to vehicle treated rats and this was asso-
ciated with an increased mRNA and protein expression 
of endothelial nitric oxide synthase (eNOS) in ischaemic 
brain tissue at these acute time points following MCAO. 
In addition, concentration levels of BK and its receptors 
were shown to be upregulated in ischaemic cortex fol-
lowing Ang-(1–7) treatment between 6 and 48  h post 
tMCAO [70, 78].
Similarly, 4-week chronic Ang-(1–7) infusion prior to 
MCAO was shown to increase protein levels of eNOS 
and NO concentration in the ischaemic hemisphere 
whereas iNOS and neuronal (nNOS) expression were 
unchanged. Interestingly, brain VEGF protein levels were 
also elevated, an outcome associated with an increase in 
angiogenic markers (CD31 and EdU). Following pMCAO, 
Ang-(1–7) reduced infarct volume and improved CBF an 
effect specific to the MasR, suggesting that Ang-(1–7) 
activates Mas/eNOS signalling pathways, improving 
angiogenesis and cerebral perfusion [72]. Still, the impact 
of Ang-(1–7) on CBF is under debate as Mecca et al. [26] 
reported that central infusion of Ang-(1–7) for 7  days 
prior to ET-1 induced MCAO did not affect CBF when 
measured during MCAO.
Targeting the MasR with Ang-(1–7) is showing promis-
ing results in experimental stroke models however, Ang-
(1–7) has a 20 s half life in the bloodstream and is unlikely 
to cross the BBB therefore necessitating specific receptor 
agonists to be developed with improved pharmacokinetic 
profiles [79]. As a result, in order to see an effect follow-
ing AIS, it has had to be administered centrally, a route of 
administration which is not clinically feasible. At present, 
Mas agonist, AVE0991 has been developed, however, 
following tMCAO in mice, i.p AVE0991 post-treatment 
failed to induce similar neuroprotective as observed in 
Ang-(1–7) treated studies [73].
The effect of ARBs in clinical trials
In clinical trials, the effectiveness of ARB treatment in 
preventing vascular events and mortality following AIS 
is under debate. The LIFE trial compared losartan (AT1R 
antagonist) and atenolol (selective β1  receptor blocker) 
treatment for preventing cerebral ischaemic events 
in patients with a clinical history of hypertension and 
left ventricular hypertrophy. After a follow up time of 
4.8 years, the authors demonstrated that the use of losar-
tan was associated with a decrease in the frequency of 
stroke [80]. Moreover the ACCESS trial was designed to 
assess the efficacy of a modest blood pressure reduction 
acutely after stroke (day 1 post stroke for 7  days) with 
patients receiving either candesartan cilexetil (AT1R 
antagonist) or placebo treatment. Although the trial 
was stopped early it did demonstrate a reduced number 
of vascular events and decreased mortality in the can-
desartan treatment group [81]. In following years, the 
MOSES study investigated the effects of eprosartan or 
nitrendipine (calcium channel blocker) in hypertensive 
patients who had a cerebrovascular event within the last 
24 months prior to recruitment. After 2.5 years follow up, 
it was identified that eprosartan group showed signifi-
cantly less cases of cardiovascular and cerebrovascular 
events [82]. Furthermore, telmisartan, as an alternative 
therapy for cardiovascular disease patients who are intol-
erant to ACE inhibitors, was shown to induce a modest 
reduction in stroke incidence [83].
Despite the benefits of AT1R antagonism observed, 
other studies showed contradictory effects. For instance, 
a study assessing whether blood pressure lowering with 
telmisartan treatment in ischaemic stroke patients 
affected the risk of recurrent cerebral events concluded 
after a 2.5 year follow up that telmisartan did not affect 
the risk of recurrent stroke nor other cardiovascular 
events [84]. More recently, the SCAST clinical trial inves-
tigated whether blood pressure lowering with candesar-
tan in acute stroke patients is beneficial. After 6 months 
follow up, no beneficial effect of blood pressure lowering 
with candesartan was observed with no difference in the 
occurrence of vascular events. Plus, for functional out-
come there was a less favourable modified Rankin score 
in the candesartan group albeit this was not statistically 
significant [85]. The results from clinical trials to date 
have primarily investigated the influence of modulation 
of the RAS in terms of stroke incidence or blood pressure 
lowering strategies following stroke however, the effect of 
RAS modulation acutely after ischaemic stroke in terms 
of outcome (i.e. penumbral salvage, lesion volume) has 
yet to be fully investigated.
Conclusions
The RAS is currently a therapeutic target for the treat-
ment of AIS. Pathological activation of the ‘classical 
axis’ contributes towards ischaemic injury develop-
ment and the ‘alternative axis’ is thought to counteract 
these effects leading to protection. Interestingly, the 
pathology of stroke co-morbidities such as hyperten-
sion and gender are all influenced by RAS dysfunction, 
where there is an increased/overactive ACE/Ang II/
AT1R pathway. Consequently, targeting the RAS could 
act as a preventive line of therapy for the develop-
ment of stroke and attenuate injury following stroke by 
diminishing brain RAS imbalances or providing direct 
neuroprotection.
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Several preclinical studies have identified the potential 
neuroprotective effect of AT1R blockers, AT2R and MasR 
agonists. ARBs have been extensively studied in the con-
text of experimental stroke due to its current clinical use 
in hypertension management. Although there were indi-
cations of a level of neuroprotection induced by ARBs, 
its clinical potential has been set aside due to clinical tri-
als that showed that ARBs may induce harmful effects in 
ischaemic stroke patients. On the other hand, AT2R and 
MasR agonism are showing promising effects in preclini-
cal stroke models; however, further studies have to be 
conducted to identify the actual mechanisms induced 
following stroke, addressing several limitations associ-
ated to preclinical stroke.
Further understanding of the role of the RAS follow-
ing ischaemic stroke, in particular the role of the ACE2/
Ang-(1–7)/Mas pathway and development of improved 
pharmacological drugs targeting the central RAS compo-
nents are needed before any successful translation would 
be possible.
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